Jazz Pharmaceuticals plc (FRA:J7Z)
Germany · Delayed Price · Currency is EUR | Market Cap | 12.18B +102.2% |
| Revenue (ttm) | 3.85B +9.2% |
| Net Income | 25.54M -93.9% |
| EPS | 0.41 -93.7% |
| Shares Out | n/a |
| PE Ratio | 476.99 |
| Forward PE | 8.97 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | n/a |
| Open | 192.10 |
| Previous Close | 194.50 |
| Day's Range | 192.10 - 198.50 |
| 52-Week Range | 88.78 - 208.00 |
| Beta | n/a |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | May 5, 2026 |
About Jazz Pharmaceuticals
Jazz Pharmaceuticals plc identifies, develops, and commercializes pharmaceutical products in the United States, Europe, and internationally. The company offers Xywav to treat cataplexy or excessive daytime sleepiness (EDS) with narcolepsy and idiopathic hypersomnia (IH); Epidiolex for seizures associated with Lennox-Gastaut syndrome (LGS), Dravet syndrome (DS), or tuberous sclerosis complex (TSC); Rylaze for the treatment of acute lymphoblastic leukemia or lymphoblastic lymphoma; Enrylaze to treat acute lymphoblastic leukemia and lymphoblastic ... [Read more]
News
Jazz Pharmaceuticals Transcript: Jefferies Global Healthcare Conference 2026
The company has evolved into a diversified biopharma, advancing key oncology and neuroscience assets, notably zanidatamab, which has shown superior efficacy in HER2-positive cancers. Rapid regulatory progress, robust clinical data, and active partnership discussions position the pipeline for significant growth.
Jazz Pharmaceuticals Proxy statement: Proxy filing
Jazz Pharmaceuticals filed a proxy statement on May 29, 2026, providing details for shareholder voting and corporate governance matters.
Jazz Pharmaceuticals Phase 3 HERIZON-GEA-01 results published in NEJM
The company states: “Jazz Pharmaceuticals (JAZZ) announced that the New England Journal of Medicine has published the Phase 3 HERIZON-GEA-01 trial results, further characterizing the efficacy and safe...
Phase 3 HERIZON-GEA-01 Results Published in The New England Journal of Medicine Show Durable and Consistent Survival Benefit with Ziihera® (zanidatamab-hrii) Combinations in First-Line HER2+ Locally Advanced or Metastatic GEA
Expanded safety, subgroup, progression-free survival sensitivity and subsequent therapy analyses further characterize the consistency and durability of outcomes observed with zanidatamab-containing co...
Jazz Pharmaceuticals Transcript: 7th Annual Oncology Innovation Summit: Insights for ASCO & EHA
Zanidatamab is advancing toward potential approval in frontline GEA with a PDUFA date of August 25th, supported by strong clinical data and broad label potential. Expansion into breast cancer and other tumor types is ongoing, while ZEPZELCA's frontline launch in small cell lung cancer is driving revenue growth.
Jazz Pharmaceuticals price target raised to $253 from $234 at Barclays
Barclays raised the firm’s price target on Jazz Pharmaceuticals (JAZZ) to $253 from $234 and keeps an Overweight rating on the shares. An expert call indicates Jazz has “robust” patent…
Jazz Pharmaceuticals price target raised to $301 from $232 at Piper Sandler
Piper Sandler raised the firm’s price target on Jazz Pharmaceuticals (JAZZ) to $301 from $232 and keeps an Overweight rating on the shares. Jazz shares, in the firm’s view, have…
Bernstein starts Jazz at Market Perform, says clock ticking on blockbuster drugs
Bernstein initiated coverage of Jazz Pharmaceuticals (JAZZ) with a Market Perform rating and $229 price target The firm believes investors should pass on Jazz because the current share price gives…
Jazz Pharmaceuticals initiated with a Market Perform at Bernstein
Bernstein initiated coverage of Jazz Pharmaceuticals (JAZZ) with a Market Perform rating and $229 price target
Jazz Pharmaceuticals Transcript: RBC Capital Markets Global Healthcare Conference 2026
Zanidatamab shows strong efficacy and differentiation in HER2-positive cancers, with robust survival data and synergy with immunotherapies. Commercial teams are ready for launch, and expansion into new indications and partnerships is underway. The company also advances its sleep, epilepsy, and rare disease franchises.
Jazz Pharmaceuticals upgraded to Buy from Neutral at UBS
UBS analyst Ashwani Verma upgraded Jazz Pharmaceuticals (JAZZ) to Buy from Neutral with a price target of $307, up from $188. The firm cites improved confidence in Jazz’s base business…
Jazz Pharmaceuticals to Participate in Upcoming Investor Conferences
DUBLIN, May 12, 2026 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced that company management will participate in fireside chats at the following investor conferences: 2026 RBC ...
Jazz Pharmaceuticals price target raised to $245 from $226 at Morgan Stanley
Morgan Stanley analyst Sean Laaman raised the firm’s price target on Jazz Pharmaceuticals (JAZZ) to $245 from $226 and keeps an Overweight rating on the shares.
ALX Oncology evorpacept combination data presented at ESMO congress
ALX Oncology (ALXO) announced that data from exploratory analyses in the Phase 1b/2 clinical trial evaluating the company’s investigational CD47-inhibitor evorpacept in combination with Jazz Pharmaceu...
Jazz Pharmaceuticals price target raised to $234 from $225 at Barclays
Barclays analyst Etzer Darout raised the firm’s price target on Jazz Pharmaceuticals (JAZZ) to $234 from $225 and keeps an Overweight rating on the shares following the Q1 report. Jazz…
Jazz Pharmaceuticals price target raised to $252 from $209 at Baird
Baird raised the firm’s price target on Jazz Pharmaceuticals (JAZZ) to $252 from $209 and keeps an Outperform rating on the shares. The firm updated its model following Q1 results…
Jazz Pharmaceuticals price target raised to $275 from $220 at TD Cowen
TD Cowen raised the firm’s price target on Jazz Pharmaceuticals (JAZZ) to $275 from $220 and keeps a Buy rating on the shares. The firm said total Q1 revenue of…
Jazz Pharmaceuticals price target raised to $239 from $227 at Raymond James
Raymond James analyst Tiago Fauth raised the firm’s price target on Jazz Pharmaceuticals (JAZZ) to $239 from $227 and keeps an Outperform rating on the shares. JAZZ is up 25%…
Jazz Pharmaceuticals Earnings Call Transcript: Q1 2026
Record Q1 revenues grew over 19% year-over-year, led by strong commercial execution in sleep, epilepsy, and oncology. Pipeline advances include FDA priority review for Ziihera in GEA and robust cash flow supports continued investment and M&A.
Jazz Pharmaceuticals Earnings release: Q1 2026
Jazz Pharmaceuticals released its Q1 2026 earnings on May 5, 2026, summarizing the period's financial results.
Jazz Pharmaceuticals Quarterly report: Q1 2026
Jazz Pharmaceuticals has published its Q1 2026 quarterly earnings report on May 5, 2026.
Jazz Pharmaceuticals Slides: Q1 2026
Jazz Pharmaceuticals has posted slides in relation to its Q1 2026 quarterly earnings report, which was published on May 5, 2026.
Jazz Pharmaceuticals reports Q1 adjusted EPS $6.34, consensus $4.66
GAAP EPS was $4.43. Reports Q1 revenue $1.07B, consensus $979.01M. “Our first-quarter results reflect disciplined execution across the business, delivering 19% year-over-year growth alongside key pipe...
Jazz Pharmaceuticals sees FY26 revenue $4.25B-$4.5B, consensus $4.45B
16:10 EDT Jazz Pharmaceuticals (JAZZ) sees FY26 revenue $4.25B-$4.5B, consensus $4.45B